Dutch regulators probe Biogen over MS drug and blood tests

· Health · Netherlands

Dutch antitrust regulators are investigating allegations that Biogen abused a dominant position in the market for multiple sclerosis treatments and associated blood tests, STAT reported. The probe focuses on Biogen’s MS drug business and testing linked to those treatments. Biogen is a major pharmaceutical and biotechnology company. The immediate effect is added regulatory scrutiny for Biogen’s MS franchise; the report did not disclose the status or potential remedies of the investigation.

Why it matters：Antitrust scrutiny of drug-plus-test practices could affect how MS therapies and companion tests are sold and signals regulators are looking beyond pricing.

Key points

  • Dutch antitrust regulators are investigating the allegations.
  • The probe covers MS treatments and associated blood tests.
  • Biogen is alleged to have abused a dominant position.

Sources (original reporting)

More stories from this day